LAPS Rec'd PCT/PTO 08 JUN 2006

Pet

JUN 0 8 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ZICANT(s): Esteve-Soler, et al.

SERIAL NO.: 10/536,780

ART UNIT:

FILING DATE:

5/26/05

EXAMINER:

TITLE:

USE OF 2,5-DIHYDROXYBENZENESULFONIC COMPOUNDS

FOR THE MANUFACTURE OF A MEDICAMENT

ATTORNEY

DOCKET NO.:

785-012247-US (PAR)

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b)(3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

WO 97/37647

FR 2.201.888

"Calcium Dobesilate: Pharmacology and Future Approaches", T. Tejerina et al., Gen. Pharmac. Vol. 31, No. 3, pp.357-360, 1998

"Oral Drug Delivery, Small Intestine & Colon", Encyclopedia of Controlled Drug Delivery, 1999, Vol. 2, pages 698 - 728 "Drugs and the Pharmaceutical Sciences, Modified-Release Drug Delivery Technology", Michael J. Rathbone, et al., Table of Contents

"Encyclopedia of Pharmaceutical Technology, Second Edition",
James Swarbrick, Table of Contents

"Modern Pharmaceutics, Fourth Edition, Revised and Expanded",
Gilbert S. Banker, et al., Table of Contents

"The Theory and Practice of Industrial Pharmacy", Leon Lachman,
Ph. D., et al., 1986, Table of Contents

"Coated dosage forms for colon-specific drug delivery", Claudia S. Leopold, PSTT Vol. 2, No. 5 May 1999, pages 197 - 204

"Controlled Drug Delivery, Volume I, Basic Concepts", Stephen D. Bruck, Ph. D., Table of Contents

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,

Geza & Ziegler Jr.

Reg. No. 44,004

PERMAN & GREEN, LLP 425 Post Road Fairfield, CT 06824 Customer No. 2512 5 JUNE 2006
Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope address to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 0 000

Signature

3

JUN 0 8 2006

Page No.: 1 of: 1

INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION

Dock No.: 785-012247-US (PAR)

Serial No.: 10/536,780

(FORM PTO-1449)

Applicant(s): Esteve-Soler, et al.

(Substitute)							
			Filing Date: 5/26/05		Group:		
			U.S. PATENTS				
Initials	Patent Number	Issue Date	Name		Class	Sub- class	Filing date
				-			
					}		
			U.S. PATENT PUBL	ICATIONS			
Initials	Publication No.	Pub. Date	Name		Class	Sub-	Filing Date
						class	
						,	
	1	FO	REIGN PATENT DOC	UMENTS			- 4,2 400.
Initials	Document Number	Date	Country		Nam	Translation? Yes/No/n/a	
`	WO 97/37647	10/16/97	PCT	Laboi	aboratorios Del Dr.		No
				Estev	Esteve, S.A.		
	FR 2.201.888	5/3/74	France		Laboratorios Del Dr. No		
				Estev	e, S.A.		
	4	0					
			NTS (Title, Author, D				· · · · · · · · · · · · · · · · · · ·
			ology and Future Appro	aches", T. Tejei	ina et al.,	Gen. Pha	rmac. Vol.
	31, No. 3, pp.357-			1' 00	11 15	D ('	1000 77.1
			estine & Colon", Encyc	opedia of Cont	rolled Dr	ug Delivei	y, 1999, Vol.
	2, pages 698 – 72		Sciences Modified Rel	ease Drug Deli	very Tech	mology"	Michael I
	"Drugs and the Pharmaceutical Sciences, Modified-Release Drug Delivery Technology", Michael J. Rathbone, et al., Table of Contents						
			cal Technology, Second	Edition", James	Swarbrie	ck, Table	of Contents
			h Edition, Revised and E				
	Contents						<u></u> -
	1	Practice of In	dustrial Pharmacy", Lec	n Lachman, Ph	. D., et al	., 1986, Ta	able of
	Contents		-		44 = 4		
			n-specific drug delivery'	', Claudia S. Le	opold, PS	STT Vol. 2	2, No. 5 May
	1999, pages 197 –		lama I Davis C	Chamber D. D.	nul- DL	D Table	of Country to
Б		Delivery, Vo	lume I, Basic Concepts"				or Contents
	er's Signature:	rod whether an	not citation is in conformanc		Considere		at considered
munal 1			not citation is in conformanc ation form with your next co				o considerea.
						or No + 251	

Customer No.: 2512